Dual Oligonucleotide mRNA Recognition System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antisense oligonucleotide therapies lack specificity and selectivity, leading to off-target effects and clinical side effects due to non-specific binding to inadvertent mRNA molecules, which is a significant challenge in anticancer therapies targeting fusion genes.
Innovation Solution
A system comprising two sequence-specific oligonucleotides interconnected by a size-specific polymeric moiety that recognizes and forms a stable heteroduplex with target mRNA, minimizing non-specific interactions and allowing for selective and specific recognition and intervention of defined sequences, particularly in fusion genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antisense oligonucleotides are used to target mRNA, then therapeutic intervention is achieved, but specificity and selectivity are insufficient leading to off-target effects
Solution Approach 1:
The patent divides a single antisense oligonucleotide into two separate oligonucleotides that must bind to different sites on the target mRNA. This segmentation ensures that both binding events must occur simultaneously for therapeutic effect, dramatically increasing specificity and eliminating off-target effects that plague single-oligonucleotide approaches.
Solution Approach 2:
The patent combines two sequence-specific oligonucleotides into a single construct where both must bind to the target mRNA to achieve therapeutic intervention. This merging of multiple recognition elements into one functional unit ensures that only the correct dual-target mRNA will be affected, resolving the specificity problem.
2Strength
If chemical modifications are made to enhance binding affinity, then therapeutic effect is improved, but selectivity decreases and silencing of off-target genes occurs
Solution Approach 1:
By segmenting the therapeutic effect into two separate binding events, the patent allows each oligonucleotide to have moderate binding affinity while the combined effect achieves high selectivity. This segmentation prevents strong binding from causing off-target silencing, as both specific sites must be bound simultaneously.
Solution Approach 2:
The patent changes the binding parameter from single-event high-affinity binding to dual-event moderate-affinity binding. This parameter change maintains therapeutic effectiveness while dramatically improving selectivity, as the probability of both off-target sites being bound simultaneously is extremely low.
3Adaptability or versatility
If fusion genes are targeted to achieve selective anticancer therapy, then tumor cells can be treated without affecting healthy cells, but current antisense strategies lack sufficient binding specificity to achieve this selectivity
Solution Approach 1:
The patent segments the recognition of fusion genes into two distinct oligonucleotide binding sites, one targeting each fusion partner sequence. This segmentation enables highly specific recognition of the unique fusion mRNA structure while leaving healthy cell mRNAs unaffected, achieving the desired selective therapeutic action.
Solution Approach 2:
The patent uses two oligonucleotides as intermediaries that must both bind to the fusion mRNA to achieve therapeutic effect. This intermediary approach allows indirect but highly specific targeting of fusion genes, as the dual-binding requirement acts as a molecular gatekeeper that only the correct fusion mRNA can satisfy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the specificity and selectivity of nucleic acid recognition, enabling targeted therapeutic intervention in tumor cells while avoiding healthy cells, thus providing a revolutionary tool for anticancer therapy with reduced side effects.
Implementation Method 1
each of the sequence-specific oligonucleotides targets a pre-defined target sequence of the mRNA resulting in a stable heteroduplex
Data Source
AI summary
A method of altering the functional state of any nucleic acid enabling its selective and specific recognition and subsequent selective manipulation and a universal principle for increasing the specificity and selectivity of molecular target recognition at the level of nucleic acids are described. The principle of the specific and selective recognition of nucleic acids is based on simultaneous recognition of two or more sequences of the target nucleic acid, whereas these have to be spaced from each other by a certain defined distance. Such method of nucleic acid recognition through specific recognition of well-defined sequences of the nucleic acid that are spaced from each other by a defined distance, minimizes the probability of stable binding of the interfering construct to inadvertent nucleic acids, thereby dramatically increasing the selectivity of recognition of the targeted nucleic acid. Specific recognition of defined sequences of a nucleic acid localized at a certain defined distance from each other is achieved by simultaneous complementary interference of short sequence-specific oligonucleotides being mutually interconnected by size-specific linking moiety.